Oculis Holding AG (OCS)
Oculis Holding AG is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and other international markets. The company’s pipeline includes OCS-01, a topical dexamethasone Optireach formulation being studied in Phase 3 trials for diabetic macular edema; OCS-02, a topical biologic candidate in Phase 2b development for dry eye disease; and OCS-05, a neuroprotective candidate being explored for neurological damage and related indications such as glaucoma, dry age-related macular degeneration, diabetic retinopathy, and acute optic neuritis. Founded in 2017 and based in Zug, Switzerland, the company changed its name from Oculis SA to Oculis Holding AG in March 2023. The listed security is common stock on the NASDAQ under the symbol OCS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OCS
|
$9.40
|
-20.4% Downside
|
Overvalued
|
$37.41
|
216.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-6.1x
|
2.9x
|
514.5x
|
708.4 M
|
445 M
|
0.4%
|
86.3%
|
4.5
|
—
|
66.6%
|
